Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis

被引：0

作者：

Franken, M. ^{[1
]}

Van Rooijen, E. ^{[2
]}

Van Tinteren, H. ^{[3
]}

May, A. ^{[4
]}

Mol, L. ^{[5
]}

Ten Tije, A. ^{[6
]}

Creemers, G. J. ^{[7
]}

Van der Velden, A. ^{[8
]}

Van der Torren, A. ^{[9
]}

Uyl-de Groot, C. ^{[2
]}

Punt, C. ^{[10
]}

Koopman, M. ^{[1
]}

Van Oijen, M. ^{[10
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[2] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands

[3] Netherlands Canc Inst, Dept Biostat, Amsterdam, Netherlands

[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands

[5] Comprehens Canc Ctr Netherlands, Nijmegen, Netherlands

[6] Amphia Hosp, Dept Med Oncol, Breda, Netherlands

[7] Catharina Hosp, Dept Med Oncol, Eindhoven, Netherlands

[8] Tergooi Hosp, Dept Med Oncol, Hilversum, Netherlands

[9] Groene Hart Hosp, Dept Med Oncol, Gouda, Netherlands

[10] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31041-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2119

引用

页码：S370 / S370

页数：1

共 50 条

[1] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
Sherman, Scott K.
Lange, Joel J.
Dahdaleh, Fadi S.
Rajeev, Rahul
Gamblin, T. Clark
Polite, Blase N.
Turaga, Kiran K.
[J]. JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
[2] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
Goldstein, Daniel A.
Chen, Qiushi
Ayer, Turgay
Chan, Kelvin K.
Virik, Kiran
Hammerman, Ariel
Brenner, Baruch
Flowers, Christopher
Hall, Peter
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
Franken, M. D.
van Rooijen, E. M.
May, A. M.
Koffijberg, H.
van Tinteren, H.
Mol, L.
ten Tije, A. J.
Creemers, G. J.
van der Velden, A. M. T.
Tanis, B. C.
Groot, C. A. Uyl-de
Punt, C. J. A.
Koopman, M.
van Oijen, M. G. H.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
[4] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
Goldstein, Daniel A.
Chen, Qiushi
Ayer, Turgay
Chan, Kelvin K. W.
Virik, Kiran
Hammerman, Ariel
Brenner, Baruch
Flowers, Christopher R.
Hall, Peter S.
[J]. ONCOLOGIST, 2017, 22 (06): : 694 - 699
[5] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
Goldstein, Daniel A.
Chen, Qiushi
Howard, David H.
Lipscomb, Joseph
Ayer, Turgay
El-Rayes, Bassel F.
Flowers, Christopher
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
Shiroiwa, Takeru
Fukuda, Takashi
Tsutani, Kiichiro
[J]. CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
[7] BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
Fortune-Greeley, A.
Cornell, P.
[J]. VALUE IN HEALTH, 2010, 13 (03) : A34 - A34
[8] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
Peria, F. M.
Ungari, A. Q.
Dos Santos, F. N.
Lins-Almeida, T.
Nunes, A. A.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[9] Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
Lange, Joel
Rajeev, Rahul
Gamblin, T. Clark
Turaga, Kiran
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[10] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
Lakdawalla, D.
Penrod, J.
Maclean, R.
Humphrey, J. S.
Seabury, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)

← 1 2 3 4 5 →